Is Bliss GVS Pharma a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Bliss GVS Pharma Ltd is a average quality company .

Is Bliss GVS Pharma undervalued or overvalued?

The key valuation ratios of Bliss GVS Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Bliss GVS Pharma share price return in the past 10 years?

Bliss GVS Pharma Ltd share price has declined -1.3% annually (CAGR) over the past ten years.

Is Bliss GVS Pharma a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Bliss GVS Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Bliss GVS Pharma Ltd - Stock Valuation and Financial Performance

Name: Bliss GVS Pharma
Brand: Bliss GVS Pharma

BSE: 506197 | NSE: BLISSGVS | Pharmaceuticals & Drugs | Small Cap

Place order

Bliss GVS Pharma Share Price

₹161.40 4.60 2.93%
as on 18-Jul'25 16:59

Bliss GVS Pharma Ltd - Stock Valuation and Financial Performance

BSE: 506197 | NSE: BLISSGVS | Pharmaceuticals & Drugs | Small Cap

Place order

Bliss GVS Pharma Share Price

₹161.40 4.60 2.93%
as on 18-Jul'25 16:59

10 Year X-Ray of Bliss GVS Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	23.4%	19.3%	15.6%	18.8%	17.8%	12%	14.7%	12.9%	7.4%	9.3%	-
Value Creation Index ⓘ	0.7	0.4	0.1	0.3	0.3	-0.1	0.1	-0.1	-0.5	-0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	326	348	298	427	442	466	636	598	605	667	667
Sales YoY Gr.	-	6.6%	-14.4%	43.2%	3.6%	5.3%	36.7%	-6%	1.2%	10.2%	-
Adj EPS ⓘ	5.4	5.8	5.2	5.4	7	6	7.5	5.6	6.6	5.2	6.5
YoY Gr.	-	6.9%	-10.8%	4.3%	29.6%	-13.2%	23.3%	-24.7%	16.8%	-20%	-
BVPS (₹) ⓘ	41.9	47.7	52.5	58.5	66.2	72.3	81.2	89.1	93.7	99.9	99.8
Adj Net Profit ⓘ	55.7	59.5	53.2	55.3	71.8	62.3	77.3	58.4	68.6	55.2	69
Cash Flow from Ops. ⓘ	59.6	38.5	22.7	48.3	63.2	67	114	43.8	82.2	97.2	-
Debt/CF from Ops. ⓘ	1.4	2	4.1	1.5	1.4	1.3	0.8	1.8	0.8	0.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	8.3%	8.6%	1.6%	10.2%
Adj EPS ⓘ	-0.3%	-5.5%	-11.1%	-20%
BVPSⓘ	10.1%	8.6%	7.2%	6.6%
Share Price	-1.3%	8.5%	25.9%	46.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	13.9	12.9	10.3	9.7	11.2	8.7	9.6	6.5	7.1	5.4	6.6
Op. Profit Mgn % ⓘ	29.6	29	29.7	22.4	22.7	19.7	17.2	15.1	17.7	13.8	13.7
Net Profit Mgn % ⓘ	17.1	17.1	17.9	13	16.2	13.4	12.1	9.8	11.3	8.3	10.3
Debt to Equity ⓘ	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0
Working Cap Days ⓘ	527	533	621	442	443	471	372	419	400	342	210
Cash Conv. Cycle ⓘ	206	206	270	269	307	293	212	233	242	236	173

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 6.60%

Sales growth is good in last 4 quarters at 12.46%

Sales growth has been subdued in last 3 years 1.59%

Net Profit has been subdued in last 3 years -11.07%

Latest Financials - Bliss GVS Pharma Ltd.

	Standalone	Consolidated
TTM EPS (₹)	6.5	8
TTM Sales (₹ Cr.)	667	810
BVPS (₹.) ⓘ	99.8	99
Reserves (₹ Cr.) ⓘ	1,042	1,034
P/BV ⓘ	1.62	1.63
PE ⓘ	24.69	20.20

From the Market
52 Week Low / High (₹)	105.05 / 184.95
All Time Low / High (₹)	0.04 / 230.00
Market Cap (₹ Cr.)	1,703
Equity (₹ Cr.)	10.6
Face Value (₹)	1
Industry PE ⓘ	42.6

Management X-Ray of Bliss GVS Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Bliss GVS Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

No data found!

Key Ratios of Bliss GVS Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	326	348	298	427	442	466	636	598	605	667
Operating Expenses ⓘ	230	247	209	333	342	374	527	508	498	576
Manufacturing Costs	27	6	6	8	11	14	18	17	26	25
Material Costs	114	167	146	225	237	253	344	315	299	346
Employee Cost	22	25	26	34	44	59	65	73	83	99
Other Costs ⓘ	67	49	31	67	50	48	100	104	90	105
Operating Profit ⓘ	97	101	88	93	100	91	109	90	107	92
Operating Profit Margin (%)	29.6%	28.9%	29.7%	21.8%	22.7%	19.6%	17.2%	15.1%	17.7%	13.7%
Other Income ⓘ	23	9	11	36	37	19	33	51	34	36
Interest ⓘ	14	9	7	3	7	6	4	10	6	7
Depreciation ⓘ	6	6	6	6	9	14	14	15	24	27
Exceptional Items ⓘ	0	0	0	0	0	0	3	0	-41	0
Profit Before Tax ⓘ	100	95	87	120	122	91	126	116	70	94
Tax ⓘ	35	36	30	46	29	24	34	30	20	25
Profit After Tax	66	59	57	74	92	68	93	85	51	69
PAT Margin (%)	20.1%	17.0%	19.1%	17.4%	20.9%	14.5%	14.6%	14.3%	8.4%	10.3%
Adjusted EPS (₹)	6.4	5.7	5.5	7.2	9.0	6.5	8.9	8.2	4.8	6.6
Dividend Payout Ratio (%)	8%	10%	18%	14%	6%	8%	6%	6%	10%	8%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund	432	492	541	603	683	746	841	928	981	1,052
Share Capital ⓘ	10	10	10	10	10	10	10	10	10	11
Reserves ⓘ	422	481	531	593	673	735	831	918	970	1,042
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	62	74	88	67	71	68	65	66	46	23
Long Term Debt	12	12	6	31	36	32	23	41	35	20
Short Term Debt	50	61	83	37	36	35	41	25	11	3
Trade Payables	35	64	35	31	56	67	84	76	54	60
Others Liabilities ⓘ	168	37	29	35	45	65	90	70	65	75
Total Liabilities ⓘ	697	666	694	736	855	946	1,080	1,140	1,146	1,211
Fixed Assets
Gross Block	123	81	83	93	202	211	270	385	413	478
Accumulated Depreciation	44	6	11	15	23	37	45	60	84	110
Net Fixed Assetsⓘ	79	75	72	78	179	174	224	325	330	368
CWIP ⓘ	2	2	0	43	0	2	22	3	8	21
Investmentsⓘ	21	22	19	19	19	18	18	18	19	19
Inventories	22	28	40	55	61	84	90	74	89	82
Trade Receivables	251	239	283	342	405	349	409	399	400	428
Cash Equivalents	57	84	70	93	87	120	149	85	169	171
Others Assetsⓘ	266	216	209	105	105	199	167	236	131	122
Total Assets ⓘ	697	666	694	736	855	946	1,080	1,140	1,146	1,211

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ	60	38	23	48	63	67	114	44	82	97
PBT ⓘ	100	95	87	120	122	91	124	116	111	94
Adjustment ⓘ	7	28	1	3	3	41	35	41	44	56
Changes in Working Capital ⓘ	-28	-47	-29	-26	-30	-43	-14	-76	-44	-23
Tax Paid ⓘ	-20	-37	-36	-50	-32	-23	-30	-38	-29	-30
Cash Flow From Investing Activity ⓘ	-10	-29	16	-68	-60	-62	-92	-13	-66	-78
Capex	-5	-3	-1	-59	-67	-8	-73	-94	-38	-67
Net Investments	-1	-32	3	0	0	0	3	0	44	-16
Others ⓘ	-3	5	14	-9	7	-54	-22	81	-71	5
Cash Flow From Financing Activityⓘ	-35	-15	-22	9	-6	-12	-13	-26	-21	-27
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	2	2	2	3
Net Proceeds from Borrowing ⓘ	0	0	0	24	13	2	-5	-16	-10	-15
Interest Paid ⓘ	-11	-9	-8	-3	-4	-6	-2	-6	-5	-5
Dividend Paid ⓘ	-6	-5	-6	-12	-12	-6	-5	-5	-5	-5
Others ⓘ	-18	0	-8	0	-2	-2	-2	-1	-3	-4
Net Cash Flow ⓘ	14	-6	17	-11	-3	-6	9	5	-4	-7

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	16.41	12.8	11.04	13	14.36	9.45	11.68	9.66	5.31	6.78
ROCE (%)	23.43	19.25	15.6	18.8	17.75	12.02	14.68	12.89	7.36	9.31
Asset Turnover Ratio	0.52	0.51	0.44	0.6	0.56	0.52	0.63	0.54	0.53	0.57
PAT to CFO Conversion(x)	0.91	0.64	0.4	0.65	0.68	0.99	1.23	0.52	1.61	1.41
Working Capital Days
Receivable Days	257	255	319	267	308	295	217	246	241	226
Inventory Days	25	26	42	40	48	57	50	50	49	47
Payable Days	136	108	124	54	67	88	80	93	79	61

Bliss GVS Pharma Ltd Stock News

Bliss GVS Pharma Ltd FAQs

What is the share price of Bliss GVS Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Bliss GVS Pharma on 18-Jul-2025 16:59 is ₹161.4.

What is the market cap of Bliss GVS Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-Jul-2025 16:59 the market cap of Bliss GVS Pharma stood at ₹1,702.7.

What is the P/E ratio of Bliss GVS Pharma?

The latest P/E ratio of Bliss GVS Pharma as of 18-Jul-2025 16:59 is 24.69.

What is the P/B ratio of Bliss GVS Pharma?

The latest P/B ratio of Bliss GVS Pharma as of 18-Jul-2025 16:59 is 1.62.

What is the 52-week high and low of Bliss GVS Pharma?

The 52-week high of Bliss GVS Pharma is ₹184.9 and the 52-week low is ₹105.0.

What is the TTM revenue of Bliss GVS Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bliss GVS Pharma is ₹667.2 ( Cr.) .

About Bliss GVS Pharma Ltd

Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory, anti-pyretic, analgesic, and several others.

It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, it has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities, the company is poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.

Business area of the company

It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Key Milestones

1984: Incorporated as Bliss Chemicals and Pharmaceuticals Limited.
1986: Launch of Flagship product ‘TODAY’, a vaginal contraceptive.
2006: Merger of GVS Labs with Bliss Chemicals & Pharma to form Bliss GVS Pharma Ltd.
2007: Commissioning of manufacturing units for Tablets & Dry Syrups at Palghar.
2010: Commissioning of a state-of-the-artfacility for Suppositories and Pessaries.
2011: EU-GMP approval to the manufacturing facility for suppository facility.
2015: Setting up Healthcare Centres in East Africa under Bliss GVS Healthcare.
2017: Setting up offices in South East Asian countries.
2018: Divestment from Bliss GVS Healthcare.
2019: Setting up of multi-dosage facility (Vevoor Plant).

SEBI Registered: Investment Adviser - INA000013323 RIA Details

Warning: Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer: Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provides any assurance of returns to investors.

Compliance Officer:

Name: Shrikant Jagtap

Email: shrikant.jagtap@moneyworks4me.com

Mobile No: +91 97638 00745

Grievance Officer:

Name: Mukta Vaze

Email: mukta.vaze@moneyworks4me.com

Mobile No:+91 98609 19463

Principal Officer:

Name: Atharva Bhide

Email: atharva.bhide@moneyworks4me.com

Mobile No:+91 91758 99463

SEBI regional/local office address-

Plot No. C 4-A , G Block, Near Bank of India, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra 400051

Address:

The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Data provided by Accord Fintech Pvt. Ltd.

Please wait your portfolio is updating...

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity - May 16, 2019 - Perpetual
BASL Membership ID:	BASL1187
Address	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Bliss GVS Pharma Ltd - Stock Valuation and Financial Performance

Bliss GVS Pharma Share Price

Bliss GVS Pharma Ltd - Stock Valuation and Financial Performance

Bliss GVS Pharma Share Price

DeciZen - make an informed investing decision on Bliss GVS Pharma Share

Overall Rating ⓘ

1. Quality

2. Valuation

3. Price Trend

Bliss GVS Pharma stock performance -

Is Bliss GVS Pharma Ltd an attractive stock to invest in?

1. Is Bliss GVS Pharma Ltd a good quality company?

2. Is Bliss GVS Pharma Ltd undervalued or overvalued?

3. Is Bliss GVS Pharma Ltd a good buy now?

10 Year X-Ray of Bliss GVS Pharma: Share

Analysis of Financial Track Record

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Recent Performance Summary

Latest Financials - Bliss GVS Pharma Ltd.

Management X-Ray of Bliss GVS Pharma: Share

Shareholding Pattern

Promoter's Holding & Share Pledging